MaxCyte to Pay $151.8M for Akron Bio: $105M Cash, 20.6M Shares, $20M Deferred
MXCT has more than doubled off its 52-week low of $0.643.
Summary
MaxCyte agreed to acquire Akron Bio for $151.8 million — $105.0 million cash, 20.6 million shares and $20.0 million of deferred payments — a deal expected to nearly double revenue and accelerate profitability, funded partly by a new $75.0 million MidCap credit facility.
Key Events · M&A and Partnerships · MXCT
-
Akron Bio Acquired for $151.8M
MaxCyte will pay $105.0 million cash at closing, issue 20,639,733 shares (~$26.8 million at the November 9 close) and pay $20.0 million in guaranteed deferred cash, $10.0 million each in January 2028 and January 2029.
-
Dilution and Cash Impact
The 20,639,733-share stock consideration equals about 20% of the 103,250,292 shares outstanding as of November 9, 2026. Cash and investments are guided to roughly $40-45 million at year-end 2026 after the $105.0 million cash payment and deal expenses.
-
New $75M MidCap Facility
A $55.0 million term loan plus $20.0 million revolver; MaxCyte expects to draw $20.0 million of the term loan and $2.0 million of the revolver at closing to help fund operations through profitability.
-
Closing Conditions and Lock-Up
Closing is expected before year-end 2026, subject to HSR clearance and Nasdaq listing approval of the shares — no financing condition and no stockholder vote. Sellers are locked up for six months and get registration rights.
Analysis · MXCT · Industrial Applications And Services
MaxCyte is buying Akron BioProducts from Arcline for $151.8 million — $105.0 million cash at closing, 20,639,733 shares worth roughly $26.8 million at the November 9 close, and $20.0 million of guaranteed deferred cash in 2028 and 2029. Akron is expected to add about $28 million of 2026 revenue and $7-8 million of EBITDA, nearly doubling MaxCyte's revenue base and pulling forward profitability. The cost is real: the share issuance is dilutive, cash drops to roughly $40-45 million at closing, and the company takes on a new MidCap facility of up to $75.0 million with $22.0 million drawn at close. The deal needs HSR clearance and Nasdaq listing approval but no shareholder vote and no financing condition, with closing targeted before year-end 2026.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 52.5% of the 204 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.68%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MXCT was trading at $1.36 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $134.2M. The 52-week trading range was $0.64 to $1.81. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.